CDK7-IN-6

• UNSPSC Description:

  CDK7-IN-6 is a potent and selective cyclin-dependent kinase (CDK7) inhibitor (IC50≤100 nM), extracted from patent WO2019197549 A1, compound 210. CDK7-IN-6 is > 200-fold selective for CDK7 over CDK1, CDK2, and CDK5. CDK7-IN-6 can be used for the research of cancer[1].

• Target Antigen:

  CDK

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/cdk7-in-6.html

• Solubility:

  10 mM in DMSO

• Smiles:

  ClC1=CC=CC(N2N=C(C(C)(C)O)C=C2)=C1CNC3=NC(N4CCC(CC4)N)=NC5=C(C(C)C)C=NN35

• Molecular Weight:

  524.06

• References & Citations:

  [1]Kiyean NAM, et al.Preparation of pyrazolotriazine and/or pyrazolopyrimidine derivatives as selective inhibitor of cyclin dependent kinase. WO2019197549 A1.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  2378710-04-2